Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Urology

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0090-4295(01)01010-XPMID 11445479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

  1998cited by this paper
• High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

  1998cited by this paper
• Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

  1997cited by this paper
• Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

  1997cited by this paper
• Bicalutamide ('Casodex') development: from theory to therapy.

  1997cited by this paper
• Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

  1997cited by this paper
• Bicalutamide ('Casodex') development: from theory to therapy.

  1997cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Combined androgen blockade for the treatment of metastatic cancer of the prostate.

  1996cited by this paper
• Hormone-refractory (D3) prostate cancer: refining the concept.

  1995cited by this paper
• Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

  1994cited by this paper
• Quality of life in prostate cancer

  1992cited by this paper
• Statistical Power Analysis for the Behavioral Sciences (2nd ed.)

  1989cited by this paper
• Effect Sizes for Interpreting Changes in Health Status

  1989cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• Measuring change over time: assessing the usefulness of evaluative instruments.

  1987cited by this paper
• The measurement of symptom distress.

  1987cited by this paper
• The short‐form McGill pain questionnaire

  1987cited by this paper
• Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease.

  1983cited by this paper
• Development of a symptom distress scale

  1978cited by this paper

• Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines

  2024cites this paper
• Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

  2023cites this paper
• Repurposing antifungal drugs for cancer therapy

  2022cites this paper
• Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer

  2021cites this paper
• Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors

  2020cites this paper
• New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials

  2020cites this paper
• Management of metastatic prostate cancer: recent advances, clinical perspectives and future prospects

  2019cites this paper
• Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer

  2018cites this paper
• AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells

  2018cites this paper
• Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP

  2018cites this paper
• Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database

  2018cites this paper
• The role of ketoconazole in current prostate cancer care

  2018cites this paper
• Medical management of metastatic prostate cancer.

  2018cites this paper
• Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment

  2018cites this paper
• Clinical Results of Secondary Hormonal Treatment

  2018cites this paper
• Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

  2017cites this paper
• A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer

  2017cites this paper
• Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective

  2017cites this paper
• Reply to C.G. Drake.

  2017cites this paper
• Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

  2016cites this paper
• Prostate cancer: improving outcomes in Australia through rapid access diagnostics

  2016cites this paper
• Antiandrogen Monotherapy in the Treatment of Prostate Cancer

  2016cites this paper
• Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.

  2016cites this paper
• Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

  2016cites this paper
• Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.

  2016cites this paper
• The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer

  2016cites this paper
• Triple Negative Breast Cancer: Nanosolutions for a Big Challenge

  2015cites this paper
• Implementing newer agents for the management of castrate‐resistant prostate cancer: what is known and what is needed?

  2015cites this paper
• Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer

  2015cites this paper
• A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Patients with Castration Resistant Prostate Cancer

  2015cites this paper
• Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)

  2015cites this paper
• Sequencing current therapies in the treatment of metastatic prostate cancer.

  2015cites this paper
• A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

  2015cites this paper
• Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.

  2015cites this paper
• Upon failure of first-line ADT, should second-line hormonal manipulation without survival benefit data still be used?

  2015cites this paper
• Enzalutamide: Development from bench to bedside.

  2015cites this paper
• A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer

  2014cites this paper
• Chemotherapeutic inhibitors in the treatment of prostate cancer

  2014cites this paper
• Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

  2014cites this paper
• The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.

  2014cites this paper
• Enhancing nurse contributions to SWOG clinical trials.

  2014cites this paper
• An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

  2014cites this paper
• Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.

  2014cites this paper
• Salonen Intermittent versus Continuous Androgen Deprivation in Patients with Advanced Prostate Cancer

  2013cites this paper
• 24. Endocrine Agents

  2013cites this paper
• Sequencing of agents for castration-resistant prostate cancer.

  2013cites this paper
• [Hormonal treatment in prostate cancer].

  2013cites this paper
• Guidelines on Prostate Cancer

  2013cites this paper
• Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.

  2013cites this paper
• Early vs. Delayed Hormonal Treatment in Locally Advanced orAsymptomatic Metastatic Prostatic Cancer Patient Dilemma: A Review

  2013cites this paper
• Targeting the androgen receptor.

  2012cites this paper
• Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

  2012cites this paper
• Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment

  2012cites this paper
• A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

  2012cites this paper
• Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer

  2012cites this paper
• Endocrine prevention and treatment of prostate cancer.

  2012cites this paper
• Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor‐axis in castration‐resistant prostate tumors

  2012cites this paper
• Recommendations on the management of controversies in advanced castrate-resistant prostate cancer

  2012cites this paper
• [Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].

  2012cites this paper
• Biological properties of androgen receptor pure antagonist for treatment of castration‐resistant prostate cancer: Optimization from lead compound to CH5137291

  2011cites this paper
• Hormonal Therapy in Cancer

  2011cites this paper
• Current Treatment Strategies for Castration-Resistant Prostate Cancer

  2011cites this paper
• Validity of four pain intensity rating scales

  2011cites this paper
• Secondary hormonal therapy in men with castration-resistant prostate cancer.

  2011cites this paper
• Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

  2010cites this paper
• Рак предстательной железы

  2010cites this paper
• Antiandrogens and androgen depleting therapies in prostate cancer: novel agents for an established target

  2010cites this paper
• Guía clínica sobre el cáncer de próstata

  2010cites this paper
• Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy?

  2010cites this paper
• Cáncer de próstata: terapia multimodal

  2009cites this paper
• The role of systemic cytotoxic therapy for prostate cancer

  2009cites this paper
• Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.

  2009cites this paper
• [Management of metastatic androgeno-independent prostate cancer].

  2008cites this paper
• Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.

  2008cites this paper
• Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.

  2008cites this paper
• Secondary hormonal manipulation.

  2008cites this paper
• Etude du ligand TRAIL et ses récepteurs dans la prostate normale et pathologique reliée au statut hormonal

  2008cites this paper
• Adapting treatment for prostate cancer according to risk of disease progression.

  2008cites this paper
• Hormone Therapy For Prostate Cancer

  2008cites this paper
• Metastasis of prostate cancer

  2007cites this paper
• [Prostatic cancers].

  2007cites this paper
• Biology and clinical management of prostate cancer bone metastasis.

  2007cites this paper
• Current perspectives in the treatment of advanced prostate cancer

  2007cites this paper
• Rising PSA in nonmetastatic prostate cancer.

  2007cites this paper
• Cancer de la prostate

  2007cites this paper
• Antiandrogen therapy in prostate cancer

  2007cites this paper
• Tyrosine 687 Phosphorylated Alzheimer’s Amyloid Precursor Protein Is Retained Intracellularly and Exhibits a Decreased Turnover Rate

  2007cites this paper
• Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy

  2007cites this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cites this paper
• Recent progress in hormonal therapy for advanced prostate cancer

  2006cites this paper
• An interdisciplinary approach to treating prostate cancer.

  2005cites this paper
• Diethylstilboestrol versus Bicalutamide in Hormone Refractory Prostate Carcinoma: A Prospective Randomized Trial

  2005cites this paper
• The Validity and Reliability of Pain Measures for use in Clinical Trials in Adults : Review Paper

  2004cites this paper
• Endocrine treatment of prostate cancer.

  2004cites this paper
• An evaluation of bicalutamide in the treatment of prostate cancer.

  2004cites this paper
• Bicalutamide (Casodex®) in the treatment of prostate cancer

  2004cites this paper
• Management of androgen-independent prostate cancer.

  2004cites this paper
• Treatment of hormone refractory prostate cancer

  2004cites this paper
• [Hormone therapy for prostate cancer].

  2004cites this paper
• Treatment of Prostate Cancer—The Role of Primary Hormonal Therapy

  2003cites this paper